Literature DB >> 12053089

A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.

Inge M van der Sluis1, Wim C Hop, Johannes P T M van Leeuwen, Huib A P Pols, Sabine M P F de Muinck Keizer-Schrama.   

Abstract

AIM: To provide reference data of biochemical markers of bone turnover and vitamin D metabolites for children and young adults.
METHODS: Blood samples were taken from 176 healthy Dutch children and young adults (age range 7.6-25.3 years) to assess serum calcium, alkaline phosphatase, inorganic phosphate, osteocalcin, collagen type I cross-linked N-telopeptide, N-terminal propeptide of type I procollagen, 25-hydroxyvitamin D3, and 1,25-dihydroxyvitamin D3 levels. Cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen were assessed in 286 subjects (age range 1.4-25.3 years).
RESULTS: Calcium and vitamin D levels were independent of age. The peak concentrations for collagen type I cross-linked N-telopeptide, cross-linked telopeptide of type I collagen, carboxy-terminal propeptide of type I procollagen, N-terminal propeptide of type I procollagen, alkaline phosphatase, and osteocalcin were found during puberty, in girls approximately 2.5 years earlier than in boys. Strong correlations were found between the markers of bone turnover, while no correlation was found between the markers of bone turnover and bone mineral density measured by dual-energy X-ray absorptiometry.
CONCLUSIONS: Single measurements of bone markers cannot predict bone density. Reference data according to gender, age, and Tanner stage are given which allow calculating standard deviation scores adjusted for age and gender. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053089     DOI: 10.1159/000058378

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  19 in total

1.  Bone mineral density and bone turnover in patients with Bartter syndrome.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Mireia Aguirre
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

2.  Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

Authors:  Hansjoerg Schmid; Bernadette A S Jaeger; Judith Lohse; Meinolf Suttorp
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

3.  Bone Mineral Content as a Driver of Energy Expenditure in Prepubertal and Early Pubertal Boys.

Authors:  Lynae J Hanks; Orlando M Gutiérrez; Ambika P Ashraf; Krista Casazza
Journal:  J Pediatr       Date:  2015-04-01       Impact factor: 4.406

4.  The novel bone alkaline phosphatase B1x isoform in children with kidney disease.

Authors:  Diana Swolin-Eide; Sverker Hansson; Lasse Larsson; Per Magnusson
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

5.  Adiponectin and bone metabolism markers in female rowers: eumenorrheic and oral contraceptive users.

Authors:  J Jürimäe; S Vaiksaar; J Mäestu; P Purge; T Jürimäe
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

6.  Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children.

Authors:  Kim M Waterhouse; Ari Auron; Tarak Srivastava; Connie Haney; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2006-10-11       Impact factor: 3.714

7.  Growth hormone is positively associated with surrogate markers of bone turnover during puberty.

Authors:  Melissa Russell; Anne Breggia; Nara Mendes; Anne Klibanski; Madhusmita Misra
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

8.  Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial.

Authors:  Kumaravel Rajakumar; Charity G Moore; Jonathan Yabes; Flora Olabopo; Mary Ann Haralam; Diane Comer; Jaimee Bogusz; Anita Nucci; Susan Sereika; Jacqueline Dunbar-Jacob; Michael F Holick; Susan L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2015-06-19       Impact factor: 5.958

9.  Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia.

Authors:  F K Grote; L W A Van Suijlekom-Smit; D Mul; W C J Hop; R Ten Cate; W Oostdijk; W Van Luijk; C J A Jansen-van Wijngaarden; S M P F De Muinck Keizer-Schrama
Journal:  Arch Dis Child       Date:  2005-10-13       Impact factor: 3.791

10.  Muscle weakness as presenting symptom of osteogenesis imperfecta.

Authors:  Annemieke M Boot; Rene F M de Coo; Gerard Pals; Sabine M P F de Muinck Keizer-Schrama
Journal:  Eur J Pediatr       Date:  2006-03-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.